PLIANT THERAPEUTICS INC's ticker is PLRX and the CUSIP is 729139105. A total of 56 filers reported holding PLIANT THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,071,710 | +1.5% | 2,945,312 | +6.1% | 0.00% | 0.0% |
| Q2 2023 | $50,316,667 | -20.3% | 2,776,858 | +17.0% | 0.00% | -50.0% |
| Q1 2023 | $63,114,405 | +67.5% | 2,372,722 | +21.7% | 0.00% | +100.0% |
| Q4 2022 | $37,675,021 | +12.8% | 1,949,044 | +21.9% | 0.00% | 0.0% |
| Q3 2022 | $33,410,000 | +296.2% | 1,599,324 | +51.9% | 0.00% | – |
| Q2 2022 | $8,433,000 | -2.4% | 1,052,686 | -14.6% | 0.00% | – |
| Q1 2022 | $8,642,000 | -47.5% | 1,232,699 | +1.2% | 0.00% | – |
| Q4 2021 | $16,449,000 | -31.3% | 1,218,410 | -14.1% | 0.00% | -100.0% |
| Q3 2021 | $23,946,000 | -35.3% | 1,418,599 | +11.6% | 0.00% | 0.0% |
| Q2 2021 | $37,030,000 | -14.6% | 1,271,656 | +15.3% | 0.00% | 0.0% |
| Q1 2021 | $43,369,000 | +276.6% | 1,102,685 | +117.5% | 0.00% | – |
| Q4 2020 | $11,517,000 | +15.3% | 506,959 | +15.0% | 0.00% | – |
| Q3 2020 | $9,988,000 | +1130.0% | 440,993 | +1664.0% | 0.00% | – |
| Q2 2020 | $812,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 1,839,160 | $35,550,963 | 27.86% |
| TRV GP IV, LLC | 2,132,867 | $41,228,319 | 17.53% |
| CHI Advisors LLC | 3,169,892 | $61,274,012 | 16.32% |
| GREAT POINT PARTNERS LLC | 1,322,870 | $25,571,077 | 5.01% |
| VR Adviser, LLC | 1,080,000 | $20,876,400 | 3.52% |
| Redmile Group, LLC | 3,878,599 | $74,973,319 | 3.07% |
| Casdin Capital, LLC | 1,675,000 | $32,377,750 | 2.51% |
| Fernwood Investment Management, LLC | 304,573 | $5,887,396 | 2.44% |
| Cheyne Capital Management (UK) LLP | 66,144 | $1,278,564 | 2.23% |
| First Light Asset Management, LLC | 1,057,881 | $20,448,840 | 1.90% |